Additional Relevant Details Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets, marketed by Janssen Pharmaceuticals, Inc., had annual sales of approximately $488 million in the United States, according to IMS data as of October 2015. Tri-Lo-Sprintec is indicated for use by females of reproductive potential to prevent pregnancy. Tri-Lo-Sprintec does not protect against HIV infection (AIDS) and other sexually transmitted diseases.